Younger Patients With Lung Cancer Often Have Targetable Biomarkers
Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more personalized and effective treatment.
U.S. Centers Seek Namodenoson for Pancreatic Cancer Compassionate Use
U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for patients with pancreatic cancer.
Experimental drug could spur immunotherapy response in patients with non-small cell lung cancer
